Eli Lilly & Co. (LLY)
1174.61
-1.49
(-0.13%)
USD |
NYSE |
Aug 28, 16:00
1172.99
-1.62
(-0.14%)
Pre-Market: 20:00
Eli Lilly Net Income (Quarterly) : 7.095B for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.095B |
| March 31, 2026 | 7.396B |
| December 31, 2025 | 6.636B |
| September 30, 2025 | 5.582B |
| June 30, 2025 | 5.661B |
| March 31, 2025 | 2.759B |
| December 31, 2024 | 4.410B |
| September 30, 2024 | 970.30M |
| June 30, 2024 | 2.967B |
| March 31, 2024 | 2.243B |
| December 31, 2023 | 2.190B |
| September 30, 2023 | -57.40M |
| June 30, 2023 | 1.763B |
| March 31, 2023 | 1.345B |
| December 31, 2022 | 1.938B |
| September 30, 2022 | 1.452B |
| June 30, 2022 | 952.50M |
| March 31, 2022 | 1.903B |
| December 31, 2021 | 1.726B |
| September 30, 2021 | 1.110B |
| June 30, 2021 | 1.390B |
| March 31, 2021 | 1.355B |
| December 31, 2020 | 2.117B |
| September 30, 2020 | 1.208B |
| June 30, 2020 | 1.412B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.456B |
| December 31, 2019 | 1.496B |
| September 30, 2019 | 1.254B |
| June 30, 2019 | 1.327B |
| March 31, 2019 | 561.10M |
| December 31, 2018 | 1.121B |
| September 30, 2018 | 1.094B |
| June 30, 2018 | -231.60M |
| March 31, 2018 | 1.167B |
| December 31, 2017 | -1.657B |
| September 30, 2017 | 555.60M |
| June 30, 2017 | 1.008B |
| March 31, 2017 | -110.80M |
| December 31, 2016 | 771.80M |
| September 30, 2016 | 778.00M |
| June 30, 2016 | 747.70M |
| March 31, 2016 | 440.10M |
| December 31, 2015 | 478.40M |
| September 30, 2015 | 799.70M |
| June 30, 2015 | 600.80M |
| March 31, 2015 | 529.50M |
| December 31, 2014 | 428.50M |
| September 30, 2014 | 500.60M |
| June 30, 2014 | 733.50M |
| March 31, 2014 | 727.90M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Johnson & Johnson | 5.534B |
| Merck & Co., Inc. | -1.337B |
| Pfizer Inc. | -246.00M |
| Bristol Myers Squibb Co. | 3.316B |
| Atai Beckley, Inc. | -32.55M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 22.97B |
| Total Expenses (Quarterly) | 15.88B |
| EPS Diluted (Quarterly) | 7.939 |
| Enterprise Value | 1.152T |
| Gross Profit Margin (Quarterly) | 85.78% |
| Profit Margin (Quarterly) | 30.88% |
| Earnings Yield | 2.51% |
| Operating Earnings Yield | 3.71% |
| Normalized Earnings Yield | 2.904 |